Comparative Pharmacology
Head-to-head clinical analysis: EMERPHED versus WYAMINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMERPHED versus WYAMINE SULFATE.
EMERPHED vs WYAMINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EMERPHED is a combination of ephedrine and phenylephrine. Ephedrine is a sympathomimetic amine that acts directly on alpha and beta adrenergic receptors and indirectly by releasing norepinephrine from nerve endings, causing vasoconstriction, bronchodilation, and increased heart rate and blood pressure. Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction and increased blood pressure.
Wyamine sulfate (mephentermine sulfate) is a sympathomimetic amine that acts primarily by releasing norepinephrine from presynaptic nerve terminals, with direct alpha- and beta-adrenergic receptor agonist activity. It causes vasoconstriction and positive inotropic effects, increasing cardiac output and blood pressure.
Adults: 1-2 capsules (25-50 mg ephedrine sulfate) orally every 3-4 hours as needed, not to exceed 150 mg in 24 hours.
Intramuscular injection: 15-30 mg as a single dose; may repeat in 10-15 minutes if needed. Maximum total dose: 60 mg.
None Documented
None Documented
Terminal elimination half-life: 3-6 hours (prolonged in renal impairment: up to 15 hours).
Terminal elimination half-life is 6-8 hours in adults with normal renal function (CrCl >90 mL/min).
Renal excretion of unchanged drug (~30-50%) and metabolites; minor biliary/fecal elimination (<10%).
Primarily renal; 90% excreted unchanged in urine within 24 hours. Minimal biliary/fecal elimination (<5%).
Category C
Category C
Sympathomimetic
Sympathomimetic